IBM offers free AI tools to boost Covid-19 treatment discovery

IBM offers free AI tools to boost Covid-19 treatment discovery

Max Smolaks

April 6, 2020

3 Min Read

Including genome sequencing and drug candidate data

by Max Smolaks 6 March 2020

IBM is offering free access to parts of its software and services arsenal that could help identify new treatments for Covid-19.

Theseinclude a deep search tool trained on existing Covid-19 knowledge, alist of 3,000 AI-generated molecules that have potential of beingused in treatment, and a huge genomic sequence repository.

Allof these are available immediatelyto qualified scientists and academics.

The gift of data

IBM is a major player in the healthcare industry, and while the deployment of its Watson cognitive computing engine in healthcare is being met with limited success, one of its applications is drug discovery – and that is the expertise that the company is offering in a time of crisis.

Among the software being given away to researchers is a deep search engine tool that can answer questions posed in natural language, created by ingesting multiple Covid-19 and related research datasets, including those published by the White House. Its knowledge base contained 13,335 documents as of Monday, 3 April – detailing everything from clinical trials to DNA sequences – updated daily by a team based at IBM Research Zurich.

IBM has also opened access to its Functional Genomics Platform, which contains information on millions of genes, including two million recent sequences related directly to the SARS-CoV-2.

And finally, on offer is a list of 3,000 unique molecules that could be used in Covid-19 treatments, discovered using IBM’s AI generative framework. Researchers can filter and compare molecules using a variety of graphs and visualizations, and even import additional molecules of their own.

Screenshot of IBMs Coronavirus web interface

“Itcan take up to 10 years and cost as much as $2.6 billion for a newdrug to reach market,” IBMstated on the website. “Todeal with new viral outbreaks and epidemics, such as Covid-19, weneed more rapid drug discovery processes. Generative AI models haveshown promise for automating the discovery of molecules. However,there are many challenges in applying existing generative AIframeworks to accelerate the design of novel drug candidates.”

“Forthe last two years, we have been developing robust generativeframeworks that can overcome these challenges to create novelpeptides, proteins, drug candidates, and materials. We have appliedour methodology to generate drug-like molecule candidates forCovid-19 targets. Our hope is that by releasing these novelmolecules, the research and drug design communities can acceleratethe process of identifying promising new drug candidates forcoronavirus and potential similar, new outbreaks.”

Get the newsletter
From automation advancements to policy announcements, stay ahead of the curve with the bi-weekly AI Business newsletter.